Katie Kalvaitis

ASCVD risk is elevated when HDL is lower than 40 mg/dL in men or 50 mg/dL in women, a pattern that persists even when LDL cholesterol is well-controlled.

Key takeaways: A multispecialty guide to help non-expert clinicians manage diabetes, cardiorenal and metabolic diseases has been updated.

Key takeaways: George L. Bakris, MD, an internationally recognized expert in hypertension and chronic kidney disease, passed away at age 72.

Pregnancy and parenthood can bring added concerns for elite female athletes, who often face conflicting information about safety and risks for injury associated with intense sports training regimens during pregnancy and postpartum.

In the ABYSS trial, a strategy of interrupting long-term beta-blocker treatment was not noninferior to continued use for the primary composite outcome of death, myocardial infarction, stroke or hospitalization for CV reasons.

Transcatheter mitral valve repair in addition to medical therapy led to a lower rate of CV events and hospitalizations and better health status compared with medical therapy alone for patients with HF and moderate to severe mitral regurgitation.Results of the randomized RESHAPE-HF2 trial, which assessed outcomes after transcatheter mitral valve repair with MitraClip (Abbott Vascular) for the

In patients with HF and secondary mitral regurgitation, transcatheter edge-to-edge repair was noninferior to mitral valve surgery for efficacy and was linked with fewer safety endpoint events, according to data from the MATTERHORN trial. MATTERHORN, presented at the European Society of Cardiology Congress and simultaneously published in The New England Journal of Medicine, was an

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone reduced risk for CV death and worsening HF by 16% compared with placebo, researchers reported at the European Society of Cardiology Congress.

A single combined measure of three modifiable biomarkers in healthy women at midlife was predictive of 30-year risk for future cardiovascular events, according to new research presented at the European Society of Cardiology Congress.

In patients with coronary artery disease and severe aortic stenosis undergoing transcatheter aortic valve replacement, those who also had PCI had better outcomes than those who had their CAD managed conservatively, researchers reported. The investigator-initiated NOTI3 trial, presented at the European Society of Cardiology Congress and simultaneously published in The New England Journal of